DEI

Industry leaders share their perspectives on the guidance and how it will affect sponsors moving forward.

From design and trial start-up to conduct and analysis, there is enormous potential for applications of artificial intelligence within clinical trials to have a profound impact on human health.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, discusses how the guidance should prompt better-designed oncology trials and greater diversity.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, touches on challenges that may be created by the guidance such as meeting multiple regulatory requirements.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, discusses how sponsors will need to plan ahead even further for their oncology trials.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, highlights how FDA’s multiregional clinical trials in oncology guidance encourages more diverse site locations and patient populations.

In this video interview with ACT editor Andy Studna, Kashoki, SVP, global head of regulatory strategy, discusses the new draft guidance and its emphasis on proactive planning.

Twice-yearly lenacapavir, a long-acting HIV-1 capsid inhibitor, reduced HIV infections by 96% in the Phase III PURPOSE 2 trial while showing superior efficacy over daily Truvada.

Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.

Cohort study of over 290,000 patients found disparities in cancer stage at diagnosis and survival.

Despite the substantial advertising dollars spent annually, patient recruitment remains one of the most difficult challenges that clinical research professionals encounter.

In an interview with Nico Saraceno at DPHARM 2024, Pellegrino highlights current challenges she is seeing in patient recruitment and the use of technology to identify patients.

Panel discusses the advantages that these models can provide in adding efficiencies to the clinical trial process.

In an interview with Nico Saraceno at DPHARM 2024, Smith discusses how predictive modeling and community engagement can increase diversity.

Session reveals how organizations can implement DCTs into their clinical trial planning and execution processes.

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.

Gathering hard evidence on the benefits and risks of DCT solutions.

Improving accessibility drives faster and more efficient patient enrollment and a more diverse trial population.

Study findings suggest that most qualitative systemic reviews implement a generic approach as opposed to focusing on equity, diversity, and inclusion issues.

Katsuyoshi Sugita, chief people officer and chief ethics and compliance officer at Astellas Pharma, discusses innovative methods that are improving DE&I in the industry.

In part 3 of this video interview, Jim Murphy, CEO of Greenphire addresses the increasing complexity of trial protocols and how it is affecting patient access.

In the third and final part of this conversation, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara sheds light on industry collaboration and what elements of trial design have the greatest impact on diversity.

In part 2 of this conversation, Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses the guidance and how it will affect sponsors moving forward.

In part 1 of this video interview, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara highlights how IROs are bringing care directly to patients and making them feel more comfortable.

Del Smith, PhD, co-founder & CEO of Acclinate highlights challenges sponsors may face in light of FDA releasing its Diversity Action Plan guidance.

Smith shares his initial thoughts on the guidance and what its impact will be on the industry moving forward.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit highlight the potential impact FDA's Diversity Action Plan guidance will have on industry.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit share their initial thoughts on the announcement of FDA's Diversity Action Plan guidance.

Breakout session discusses the impact of incorporating decentralized elements into oncology clinical trials on data integrity, patient safety, and regulatory approvals.

Improved diversity in clinical trials can be achieved by exploring opportunities for research in developing countries that have not historically participated in large-scale, industry-sponsored clinical trials.